Evidence map›Paper›PMID 39254830›Full record

ReviewCurrent atherosclerosis reports2024

Low LDL-C: Is It all Good News?

Jacob Hartz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jacob HartzBoston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA. jacob.hartz@cardio.chboston.org.

Funding

The Use of Mobile Health Technology and Behavioral Economics to Encourage Adherence to Statins in Adolescents with Familial HypercholesterolemiaK23HL145109 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI HARTZ, JACOB · 2019 to 2023
$849k
NIH HHS 1K23HL145109-01
6 · The paper itself

Abstract

purpose of reviewThis review presents the risks and benefits of very low LDL cholesterol and the safety of using lipid-lowering therapy to achieve these levels. RECENT

findingsA growing body of literature suggests that lower LDL cholesterol levels are associated with a reduced risk of cardiovascular disease. Further, achieving these levels with pharmaceuticals is remarkably safe. Although statins may slightly increase the risk of diabetes mellitus and hemorrhagic stroke, the benefits outweigh the risks. While recommendations from professional societies are increasingly aggressive, additional risk reduction could be achieved by setting more even ambitious LDL cholesterol goals.

Indexed as

Cardiovascular DiseasesCholesterol, LDLAnticholesteremic AgentsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaAnticholesteremic AgentsCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsAdverse effectsAtherosclerotic cardiovascular diseaseHypobetalipoproteinemiaLipid-lowering therapy

Identifiers

PMID39254830

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.